Cell Therapy

Pioneering cellular immunotherapies

Advanced Cellular Therapeutics

Our cell therapy program encompasses CAR-T cells, stem cell therapies, and other cellular immunotherapies. We provide comprehensive support for complex manufacturing and administration protocols.

Research Areas

CAR-T cell therapy trials
Stem cell transplantation
TCR-engineered T cells
NK cell therapies
Mesenchymal stem cell studies
Cellular immunotherapy

Foundational Technologies & Platforms

Engineered T-Cell Therapies

CAR-T (Chimeric Antigen Receptor T-cell): Engineering patient’s own T-cells with synthetic receptors to recognize and kill cancer cells. A pillar of modern oncology, particularly effective for blood cancers targeting CD19 and BCMA antigens.

TCR-T (T-cell Receptor T-cell): Modified T-cell receptors providing more specific targeting of intracellular tumor antigens, expanding beyond surface proteins.

TILs (Tumor-Infiltrating Lymphocytes): Harvesting immune cells directly from patient tumors, expanding them ex vivo, and reinfusing for personalized cancer immunotherapy.

Stem Cell Platforms

iPSCs (Induced Pluripotent Stem Cells): Adult cells reprogrammed to embryonic-like state, capable of differentiating into any cell type for regenerative medicine.

MSCs (Mesenchymal Stem/Stromal Cells): Multipotent stromal cells with immunomodulatory properties, used for tissue repair and immune regulation.

HSCs (Hematopoietic Stem Cells): Blood-forming stem cells used in bone marrow transplants and gene therapy for blood disorders.

Manufacturing Approaches

Autologous Therapy: Using patient’s own cells, providing personalized treatment with reduced rejection risk but requiring individual manufacturing. Allogeneic Therapy: “Off-the-shelf” cell products from healthy donors, enabling immediate availability and scalability but requiring immune compatibility considerations. Gene Editing Enhancement: Combining cell therapy with CRISPR to create more potent CAR-T cells or knock out inhibitory receptors (e.g., PD-1) for improved efficacy.

Specialized Infrastructure

We work with specialized treatment centers equipped for cell therapy administration, with protocols for managing cytokine release syndrome and other unique safety considerations.

Integrated Research Excellence

Cell therapy research requires seamless coordination of highly specialized functions. Clinical Trials Management coordinates complex manufacturing timelines, apheresis procedures, and bridging therapy protocols with specialized treatment centers. Regulatory Affairs navigates cellular therapy regulatory pathways including BLA submissions and CMC requirements. Quality Assurance ensures compliance with cell therapy manufacturing standards and monitors for adverse events like cytokine release syndrome. Data Management tracks cellular product specifications and immune cell persistence data. Biostatistics designs trials for these novel modalities, and Medical Writing develops comprehensive CMC and clinical sections for regulatory submissions.